Literature DB >> 10639567

Overexpression of vascular endothelial growth factor164 and its co-receptor neuropilin-1 in estrogen-induced rat pituitary tumors and GH3 rat pituitary tumor cells.

S K Banerjee1, M N Zoubine, T M Tran, A P Weston, D R Campbell.   

Abstract

We have shown previously that the VEGF system plays a crucial role in regulation of tumor angiogenesis during the development of estrogen-induced prolactin-secreting pituitary tumors in Fisher 344 rats. Studies also suggested that both endothelial and non-endothelial cells expressed VEGF. However, several questions concerning the VEGF signals in regulation of estrogen-induced angiogenesis in rat pituitary remained unanswered. VEGF exists in a number of isoforms in human and rodent tissue (i.e., VEGF206h/205r, VEGF189h/188r, VEGF165h/164r, VEGF145h/144r and VEGF121) that differ in their molecular masses and biological activities. The VEGF isoforms bind with two tyrosine-kinase receptors, KDR/flk-1 and flt-1. In addition, VEGF165 binds with a newly identified co-receptor, neuropilin-1, which is expressed in human endothelial cells and several types of non-endothelial cells including tumor cells. The present study was undertaken to elucidate which isoforms of VEGF are predominantly expressed in normal Fisher 344 rat pituitaries, estrogen-induced prolactin secreting rat pituitary tumors and in prolactin secreting rat pituitary tumor cell line (GH3 cell line). To identify the isoform, RT-PCR with primer pairs derived from exon 1 and exon 8 of the VEGF gene, cloning, sequencing and Western blot analysis were performed. The status of neuropilin-1 in the rat pituitaries (normal and transformed) and GH3 pituitary tumor cell line has also been investigated using RT-PCR and Western blot analysis. These studies demonstrate that normal rat pituitaries, estrogen-induced rat pituitary tumors and GH3 pituitary tumor cells expressed VEGF164 and co-receptor, neuropilin-1. The VEGF164 was the predominant form in all of these cells. The VEGF164 and neuropilin-1 mRNA and protein levels were significantly higher in the estrogen-induced pituitary tumors and GH3 tumor cell line, as compared to normal pituitary. The data suggest that both VEGF164 and neuropilin-1 may actively participate in modulation of tumor angiogenesis and the development of pituitary tumors in Fisher 344 rats.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10639567     DOI: 10.3892/ijo.16.2.253

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  21 in total

1.  Modulation of VEGF/Flk-1 receptor expression in the rat pituitary GH3 cell line by growth factors.

Authors:  Matilde Lombardero; Sergio Vidal; Robert Hurta; Alba Román; Kalman Kovacs; Ricardo V Lloyd; Bernd W Scheithauer
Journal:  Pituitary       Date:  2006       Impact factor: 4.107

2.  Global analysis of gene expression in the estrogen induced pituitary tumor of the F344 rat.

Authors:  Douglas L Wendell; Adrian Platts; Susan Land
Journal:  J Steroid Biochem Mol Biol       Date:  2006-09-26       Impact factor: 4.292

3.  Subcellular localisation of VEGF in different pituitary cells. Changes of its expression in oestrogen induced prolactinomas.

Authors:  Jorge Humberto Mukdsi; Ana Lucía De Paul; Silvina Gutiérrez; Félix Daniel Roth; Agustín Aoki; Alicia Inés Torres
Journal:  J Mol Histol       Date:  2006-05-19       Impact factor: 2.611

4.  Radiological apoplexy and its correlation with acute clinical presentation, angiogenesis and tumor microvascular density in pituitary adenomas.

Authors:  Jung-Sup Lee; Yong-Sook Park; Jeong-Taik Kwon; Taek-Kyun Nam; Tae-Jin Lee; Jae-Kyun Kim
Journal:  J Korean Neurosurg Soc       Date:  2011-10-31

5.  Structural basis for ligand and heparin binding to neuropilin B domains.

Authors:  Craig W Vander Kooi; Manuel A Jusino; Benjamin Perman; David B Neau; Henry D Bellamy; Daniel J Leahy
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-03       Impact factor: 11.205

6.  Methoxychlor-induced alterations in the histological expression of angiogenic factors in pituitary and uterus.

Authors:  Jerome M Goldman; Ashley S Murr; Angela R Buckalew; Judith E Schmid; Barbara D Abbott
Journal:  J Mol Histol       Date:  2004-05       Impact factor: 2.611

7.  Magnetic resonance imaging and biological markers in pituitary adenomas with invasion of the cavernous sinus space.

Authors:  Li-Xiong Pan; Zhong-Ping Chen; Yun-Sheng Liu; Ji-Hong Zhao
Journal:  J Neurooncol       Date:  2005-08       Impact factor: 4.130

8.  Inhibitory effects of anti-VEGF antibody on the growth and angiogenesis of estrogen-induced pituitary prolactinoma in Fischer 344 Rats: animal model of VEGF-targeted therapy for human endocrine tumors.

Authors:  Katsuhiro Miyajima; Susumu Takekoshi; Johbu Itoh; Kochi Kakimoto; Takashi Miyakoshi; Robert Yoshiyuki Osamura
Journal:  Acta Histochem Cytochem       Date:  2010-04-07       Impact factor: 1.938

9.  Gene discovery in bladder cancer progression using cDNA microarrays.

Authors:  Marta Sanchez-Carbayo; Nicholas D Socci; Juan Jose Lozano; Wentian Li; Elizabeth Charytonowicz; Thomas J Belbin; Michael B Prystowsky; Angel R Ortiz; Geoffrey Childs; Carlos Cordon-Cardo
Journal:  Am J Pathol       Date:  2003-08       Impact factor: 4.307

10.  Effect of estrogen on the blood supply of pituitary autografts in rats.

Authors:  Matilde Lombardero; Andres Quintanar-Stephano; Sergio Vidal; Eva Horvath; Kalman Kovacs; Ricardo V Lloyd; Bernd W Scheithauer
Journal:  J Anat       Date:  2009-02       Impact factor: 2.610

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.